# Tissue Regenix Group Dual revenue stream growth

- Link: https://www.directorstalkinterviews.com/tissue-regenix-group-dual-revenue-stream-growth/412737914
- Published: 2017-10-11T07:28:15+01:00
- Author: Giles Arbor

**[⌊Hardman & Co Report Report Downloads⌉⌊Hardman & Co Report Report Downloads⌉[Tissue Regenix
Group Plc** (LON:TRX) has a broad portfolio of regenerative medicine products developed
from decellularised human and porcine soft tissues for the wound care, orthopaedics,
and cardiac markets. Since the launch of DermaPure, focus has been on expanding 
in the US wound care and orthopaedic markets: in August 2017, TRX acquired CellRight
Technologies, bringing in synergistic bone regeneration technology. FY’17 results
will be the first to reflect the acquisition and will include 5 months of the enlarged
entity. The 1H’17 results presented here are for stand-alone TRX, and show organic
growth, both from the EU jv and from DermaPure, to a £1.38m total.

**Strategy:** To build a regenerative medicine business with a portfolio of products
using the proprietary dCELL platform; underpinned by compelling clinical and economic
outcomes to drive higher adoption rates; whilst retaining the strategic and corporate
flexibility that the three therapeutic corporate entities provide.

**Interims:** TRX reported 1H’17 results to end June 2017, not affected by CellRight,
with sales beating our forecast by +£0.20m to £1.38m. Net cash was better than expected
at £3.61m on 30th June, subsequently strengthened by the £40m capital increase for
working capital and the acquisition of CellRight.

**Sales:** Both DermaPure (US) and GBM-V (jv in EU) sales were above expectations
by around £0.1m each. Reported growth was +118% to £1.38m (£0.63m); note, there 
were no jv sales in 1H’16 and the accounting date changed. Transitioning to more
in-patient activity saw underlying DermaPure sales grow +13% to $1.1m.

**Acquisition:** Post-period end, TRX completed the acquisition of CellRight Technologies
in San Antonio, Texas for up to $30m/£23m, immediately giving greater exposure to
the US orthopaedic market. TRX paid 3.8x prospective EV/
 sales and 12.5x EV/EBITDA
for CellRight, which has traded profitably since 2014.

**Investment summary:** Tissue Regenix Group Plc is building commercial momentum
through three clear value drivers: sales of DermaPure in US; regulatory submission
of OrthoPure XT in EU; and agreement of a joint venture for commercialisation of
woundcare and cardiac products in Europe. CellRight will boost FY2017 and accelerate
the time to reach sustainable profitability and cash generation.

Share on:
